Location
China, Asia
Cheque size
$1M - $75M
Investment Stage
Seed
Series A
Focus Areas
Health IT
Health & Hospital Services
BioTech
Pharmaceuticals
Medical Devices
About Investor
Steven Wang is a Partner and Senior Managing Director at OrbiMed in Shanghai, focusing on healthcare equity investments of $1 M–$75 M across medical devices, pharmaceuticals, biotech and health-IT, usually at seed and Series A stages. His most recent investment is Epigenic Therapeutics, a gene-modulation therapy developer. He is based in Shanghai, China. Before OrbiMed (which he joined in 2019), he spent over 15 years in healthcare investment banking at Morgan Stanley, UBS and Rothschild, and began his career as a research scientist in allergy and immunology.
Previous investments
Epigenic Therapeutics
32M |2023
HanBio Therapeutics
40M |2022
Similar Investors
TN
Tetsu Nakajima
Japan, Asia
$100K - $5M
Pre Seed
,Seed
,BT
Binh Tran
Vietnam, Asia
$500K - $2M
Pre Seed
,Seed
,SR
Sajid Rahman
Indonesia, Asia
$100K - $1M
Pre Seed
,Seed
,KB
Kenneth Ballenegger
Hong Kong, Asia
$25K - $1M
Pre Seed
,Seed
,AC
Alan Chan
Hong Kong, Asia
$100K - $5M
Pre Seed
,Seed
,JF
Jixun Foo
Singapore, Asia
$250K - $25M
Seed
,Series A
,Is this Your Profile?
If you have any updates, please fill out our form.